Evidence map›Paper›PMID 35370703›Full record

ArticleFrontiers in pharmacology2022

KRIBB11: A Promising Drug that Promotes Microglial Process Elongation and Suppresses Neuroinflammation.

Jianbin Su, Zhihua Dou, Hongxiang Hong, Feng Xu, Xu Lu, Qun Lu, Ting Ye, Chao Huang

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Jianbin SuDepartment of Endocrinology, Affiliated Hospital 2 of Nantong University, First People's Hospital of Nantong City, Nantong, China.
Zhihua DouDepartment of Pharmacy, Nantong Third Hospital Affiliated to Nantong University, Nantong, China.
Hongxiang HongDepartment of Spine Surgery, Affiliated Hospital 2 of Nantong University, First People's Hospital of Nantong City, Nantong, China.
Feng XuDepartment of Endocrinology, Affiliated Hospital 2 of Nantong University, First People's Hospital of Nantong City, Nantong, China.
Xu LuDepartment of Pharmacology, School of Pharmacy, Nantong University, Nantong, China.
Qun LuDepartment of Pharmacy, Nantong Third Hospital Affiliated to Nantong University, Nantong, China.
Ting YeDepartment of Pharmacology, School of Pharmacy, Nantong University, Nantong, China.
Chao HuangDepartment of Pharmacology, School of Pharmacy, Nantong University, Nantong, China.
Nantong University · CNAffiliated Hospital of Nantong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Microglia are key components of the central innate immune system. The over-activation of microglia, which occurs in nervous system disorders, is usually accompanied with retractions of their ramified processes. Reversing of microglial process retraction is a potential strategy for the prevention of neuroinflammation. Our previous studies have reported some endogenous molecules and drugs that can promote microglial process elongation at conditions

Indexed as

AktKRIBB11microglianeuroinflammationprocess elongation

Identifiers

PMID35370703
PMCPMC8971675
OpenAlexW4220880054

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.